KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Equity (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Equity for 12 consecutive years, with 0.62% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 31.0% to 0.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.62% through Dec 2025, down 31.0% year-over-year, with the annual reading at 0.53% for FY2025, 24.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.62% at Xenon Pharmaceuticals, down from 0.52% in the prior quarter.
  • The five-year high for Return on Equity was 0.01% in Q4 2022, with the low at 0.62% in Q4 2025.
  • Average Return on Equity over 5 years is 0.19%, with a median of 0.15% recorded in 2022.
  • The sharpest move saw Return on Equity increased 19bps in 2022, then crashed -47bps in 2025.
  • Over 5 years, Return on Equity stood at 0.2% in 2021, then soared by 97bps to 0.01% in 2022, then tumbled by -82bps to 0.01% in 2023, then plummeted by -2952bps to 0.31% in 2024, then crashed by -100bps to 0.62% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.62%, 0.52%, and 0.42% for Q4 2025, Q3 2025, and Q2 2025 respectively.